Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OREX
Orexigen's Mysimba(TM) (Naltrexone HCl / Bupropion HCl Prolonged Release) Receives Positive CHMP Opinion Recommending Approval For Weight Management In The European Union *
Friday 12/19/2014 07:20 AM ET - Dow Jones News
Orexigen's Mysimba(TM) (naltrexone HCl / bupropion HCl prolonged release) Receives Positive CHMP Opinion Recommending Approval for Weight Management in the European Union
Friday 12/19/2014 07:20 AM ET - PR Newswire via Dow Jones News
LA JOLLA, Calif., Dec. 19, 2014 /PRNewswire/ -- Orexigen Therapeutics (NASDAQ: OREX) announced today that the Committee for Medicinal Products For Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a centralized marketing authorization for Mysimba(TM) (naltrexone HCI / bupropion HCI prolonged release), as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (>=18 years) with an initial Body Mass Index (BMI) of >= 30 kg/m(2) (obese), or >= 27 kg/m(2) to 30 kg/m(2) (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension).
EMA: Positive Recommendation On Xiapex By Swedish Orphan Biovitrum *
Friday 12/19/2014 07:19 AM ET - Foreign Wire via Dow Jones News
Here you go:
Orexigen's Mysimba(TM) (Naltrexone HCl / Bupropion HCl Prolonged Release) Receives Positive CHMP Opinion Recommending Approval For Weight Management In The European Union *
Friday 12/19/2014 07:20 AM ET - Dow Jones News
Orexigen's Mysimba(TM) (naltrexone HCl / bupropion HCl prolonged release) Receives Positive CHMP Opinion Recommending Approval for Weight Management in the European Union
Friday 12/19/2014 07:20 AM ET - PR Newswire via Dow Jones News
LA JOLLA, Calif., Dec. 19, 2014 /PRNewswire/ -- Orexigen Therapeutics (NASDAQ: OREX) announced today that the Committee for Medicinal Products For Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a centralized marketing authorization for Mysimba(TM) (naltrexone HCI / bupropion HCI prolonged release), as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (>=18 years) with an initial Body Mass Index (BMI) of >= 30 kg/m(2) (obese), or >= 27 kg/m(2) to 30 kg/m(2) (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension).
EMA: Positive Recommendation On Xiapex By Swedish Orphan Biovitrum *
Friday 12/19/2014 07:19 AM ET - Foreign Wire via Dow Jones News
View more recent headlines
Headed to $12
thus the "no brainer" label.
IMO, this goes to over $120 by end of Jan.
You are perfectly entitled to whatever you believe, but my opinion is based on years of treating Hep C patients.
It's not often that we are presented with a paradigm to cure a global disease that has devastating consequences.
One pill, once per day for either 12 or 24 weeks is a game changer for this malady.
thus I agreed with the previous poster that we should be buying on the way down. The bounce here will be dramatic IMO.
Agree. This is really a "no brainer".
sold this morning at 32.37
looking to jump back in now
GILD is on sale today.
Going to $120 per share once prescription numbers for Hep C patients come out.
IMO of course.
I agree.
Already being prescribed in the U. S.
bought is this morning pre-market at $29.50
I hope you held onto your OREX shares.
Next no brainer buy is GILD at these current prices. IMO GILD goes above $120 by end of January
It's going to fly once sales numbers for Contrave are made public.
Good entry points down here still IMO
big wall set up at that 5.76 level
OREX.
They have 800 Takeda drug reps in the field pushing Contrave in the U.S. with sales numbers to be reported in Q1.
The U.S. market alone should justify the price target. EU approval would be gravy.
JMHO
good luck!
Keep an eye on OREX.
Should break out in first Q of 2015.
ML with $9 PT
Yup.
I agree. POS is worst stock I ever owned!
CRMMF
Big day yesterday up 32% on huge volume.
Kei, I hope you still had shares.
Yes
I just pick up a nice block below $74
i was fortunate to get some of those 98's
10 stocks that may revisit their highs as the year ends
21 hours 22 minutes ago - DJNF
By Philip van Doorn, MarketWatch
A seasonal pattern suggests winners will gain even more in the weeks ahead
Howard Gold has argued that this holiday season might be a winner for the stock market, and we have prepared a special list of S&P 500 member companies that might lead the charge.
Gold, in his column on Friday, said December has been the strongest month for the Dow Jones Industrial Average (DJI) over the past century, and he also cited the Stock Trader's Almanac when saying, "rocky Octobers are usually followed by strong Novembers and Decembers."
October certainly was rocky, with the S&P 500 (SPX) sliding 6% during the first half of the month before storming back with an 8% gain in the second half, coming close to a record high of 2,018.05 on Oct. 31. It's been clear sailing during November, with the index hitting a new closing high of 2,063.75 on Friday, for a year-to-date total return (with reinvested dividends) of 14%.
The continued flow of positive economic news in the U.S., including the creation of more than 200,000 jobs for nine straight months, has overshadowed weakening economies abroad, and the decline in oil and gasoline prices has put additional cash in consumers' pockets, leading into what could be a lovely season for holiday sales.
Last week's market action was helped by a number of strong reports from retailers, including a surprise profit from Target Corp. (TGT), a 5.4% sales increase for Home Depot Inc. (HD), a 5.6% sales boost for Lowe's Cos. Inc. (LOW), and sales growth of 11% for Dollar Tree Inc. (DLTR).
According to Gold, we might see continued strong market performance until at least the end of the year for "any number of reasons: tax selling of losing stocks, professional managers buying outperforming stocks to window-dress their portfolios, and Christmas and New Year's cheer spilling over to the markets."
With that in mind, we isolated the 175 S&P 500 stocks that have returned at least 20% this year.
This list pares the big group of winners to 10 that have fallen the most from their 52-week highs:
Company Ticker Industry Closing price - Nov. 21 52-week high % pullback from 52-week high Total return - YTD
Windstream Holdings Plc. Specialty Telecommunications $9.95 $13.30 -25% 35%
Gilead Sciences Inc. Biotechnology $100.58 $116.83 -14% 34%
Safeway Inc. Food Retail $34.82 $40.25 -13% 22%
Baker Hughes Inc. Oilfield Services/ Equipment $65.83 $75.64 -13% 20%
Keurig Green Mountain Inc. Specialty Food $140.37 $158.87 -12% 88%
Walgreen Co. Drugstore Chains $67.59 $76.39 -12% 20%
CenturyLink Inc. Specialty Telecommunications $40.47 $45.67 -11% 35%
Universal Health Services Inc. Class B Hospital/ Nursing Management $103.55 $115.64 -10% 28%
Time Warner Inc. Media Conglomerates $80.05 $88.13 -9% 21%
Facebook Inc. Class A Internet Software/ Services $73.75 $81.16 -9% 35%
Total returns assume reinvestment of dividends. Source: FactSet
We have excluded two oil producers, Newfield Exploration Co. (NFX) and EOG Resources Inc. (EOG), from this list, because of the extraordinary pressure in the industry brought about by the oil-price drop. Shares of Newfield Exploration have returned 43% this year through Friday's close, yet the stock is 23% shy of its 52-week high. EOG Resources has returned 22% this year, but the stock is down 14% from its 52-week high.
One oil-related play included in the list is Baker Hughes Inc. (BHI), which last week agreed to be acquired by oil-field-services and equipment rival Halliburton Co. (HAL) for $34.6 billion in cash and stock. That is a fascinating deal, since it faces a regulatory hurdle for approval, and shares of Baker Hughes closed at $65.83 Friday, which is 16% lower than the offer price.
-Philip van Doorn; 415-439-6400; AskNewswires@dowjones.com
Copyright (c) 2014 Dow Jones & Company, Inc.
I keep accumulating on days like today.
There is no reason that I can see that this should not go to $120
The drug is actually cheap when you compare it to the cost of taking care of chronic Hep. C over the long-term.
We are talking about a cure for Hep. C for all intents.
No brainer IMO
OREX
Going up again pre-market
Orexigen Announces Allowance of New U.S. Patent for Contrave® (naltrexone HCl / bupropion HCl extended release)
SAN DIEGO, Nov. 21, 2014 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that the Company has received a notice of allowance from the U.S. Patent and Trademark Office (PTO) for U.S. Patent Application No. 11/757,773, which covers use of Orexigen's sustained release formulation of naltrexone, which was designed to improve drug tolerability for Contrave® (naltrexone HCl / bupropion HCl extended release), in a method for treating obesity. The patent is expected to expire in March of 2028. Orexigen expects the patent to be listed in the Orange Book maintained by the United States Food and Drug Administration.
"A key component of Orexigen's strategy is to strengthen and extend intellectual property protection for Contrave," said Michael Narachi, CEO of Orexigen. "We are pleased that patent protection for use of this naltrexone formulation – and for Contrave – is now expected to extend at least to 2028."
Going up over $6 this AM
Average 10 day volume here is about 6.5 million shares per day.
So they are letting go about 2 days volume at $75
Looks like a small speed bump to me and IMO a great buying opportunity?
Just buy it and forget about it until February.
Then sell it for $130
Sold my position today at 66.15 and bought GILD
I finally bought in here at 9.08
We shall see but it looks good for a run up into PDUFA
Yes
Dec. 19 should serve as a near-term catalyst here.
In the longer time frame, sales figures should push us North.
Bought the dip yesterday.
Hopefully up today.
It will bounce up today. Tuesdays have been historically good days anyways.
Agree with $120 price target by EOY.
IMO
Actually, it's even better than that. BHI shareholders get 1.12 shares of HAL for each share they own of BHI plus $19 in cash per share.
So if HAL is $50 then BHI should be north of $69
What's up with the crazy price action?
My account shows $575 per share.
Wish it were true
Great buying opportunity
GILD looks like a great buying opportunity IMO on today's pullback on the news of the offerings.
Nothing wrong with Harvoni
They are raising $4 billion in cash.
the best I could get were at 104.18
great way to trade.
love it.
GILD on the pullback today makes for a great buying opportunity. The senior notes announced today will raise $4 billion. The market is reacting to the news, but IMO, this bodes well for GILD. Earnings should be stellar.
I picked up some cheapies this AM below $105.
the recent activity and price action here makes me think that someone knows something. Looks like a great sign that perhaps something very meaningful is about to happen.
Good luck to all of us longs here.
sold my position here today at 4.15
this was like watching paint dry.
the recent activity and price action here makes me think that someone knows something. Looks like a great sign that perhaps something very meaningful is about to happen.
Good luck to all of us longs here.
Kei,
Are you still in CRMMF? It's up big.
Also, I hope you got some OREX, also up big in the past two days.